SECOND-LINE CHEMOTHERAPY IN ADVANCED CANCER OF THE
Results: Five partial responses (19%) and eight stabilizations (31%) were recorded for a tumor growth control rate of 50%. The median TTP was 4 months (range 2-7 months), and median overall survival was 6.5 months (range 3-9 months). A stabilization of PS and a subjective improvement of cancer-related symptoms was recorded in 15 patients (57%).
Conclusions: Data presented in this paper support the use of FOLFIRI regimen in the second-line treatment of APC patients.
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